Alligator Bioscience Receives FDA Endorsement for Phase 3 Mitazalimab Dose

Alligator Bioscience AB ( (SE:ATORX) ) has shared an announcement.

Alligator Bioscience announced that the FDA has endorsed the 900 µg/kg dose of its CD40 agonist mitazalimab for a planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma. This regulatory feedback marks a significant milestone for Alligator, as it finalizes its Phase 3 program for mitazalimab, and the company is actively seeking a partner to advance the drug into the next phase of development.

More about Alligator Bioscience AB

Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs that target the CD40 receptor. The company’s approach focuses on enhancing T cell priming and reversing the immunosuppressive nature of the tumor microenvironment, offering potential benefits for cancer patients across various types of cancer. Alligator’s lead drug candidate, mitazalimab, is in preparation for Phase 3 development and has shown promising results in previous trials for metastatic pancreatic cancer.

Average Trading Volume: 228,906

Current Market Cap: SEK132.7M

Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.